印度免疫学否认澳大利亚对阿巴伊拉布狂犬病疫苗的警告,并援引一份过时的批发和全球安全记录。 Indian Immunologicals denies Australian warning on Abhayrab rabies vaccine, citing one outdated batch issue and global safety record.

印度免疫组织(India Immunicistics Ltd)表示澳大利亚警告, 自2023年以来, 假冒Abhayrab狂犬病疫苗批量已过时且有误导性, Indian Immunologicals Ltd says an Australian advisory warning about counterfeit Abhayrab rabies vaccine batches since 2023 is outdated and misleading. 该公司在2025年1月确认只有一批(KA 24014)包装异常,并迅速向印度监管机构报告,不再流通。 The company confirmed only one batch (KA 24014) had a packaging anomaly in January 2025, which was promptly reported to Indian regulators and removed from circulation. 印度中央药物实验室强制测试所有二联疫苗, 该公司坚持政府授权及经销渠道继续提供安全、有效的疫苗。 All IIL vaccines undergo mandatory testing by India’s Central Drugs Laboratory, and the company insists authorized government and distributor channels continue to provide safe, effective vaccines. 自2000年以来,全球散发的剂量超过2.1亿剂,阿卜海拉布在印度的市场份额占40%。 Over 210 million doses have been distributed globally since 2000, with Abhayrab holding a 40% market share in India.